Sprycel to undergo pricing readjustments

The government plans to review the pricing feasibility of BMS's Sprycel (dasatinib), an oral inhibitor of multiple tyrosine kinases, at the meeting of an insurance price coordination committee to be first held during the second week of this month.

The price coordination committee, under the umbrella of the Ministry of Health and Family, will make a proposal to BMS, to this effect that the fi...